{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:57:41Z","timestamp":1767175061966,"version":"build-2238731810"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/1095"],"award-info":[{"award-number":["20\/1095"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) has exposed the disproportionate effects of pandemics on frontline workers and the ethical imperative to provide effective prophylaxis. We present a model for a pragmatic randomised controlled trial (RCT) that utilises Bayesian methods to rapidly determine the efficacy or futility of a prophylactic agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We initially planned to undertake a multicentre, phase III, parallel-group, open-label RCT, to determine if hydroxychloroquine (HCQ) taken once a week was effective in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in healthcare workers (HCW) aged\u2009\u2265\u200918\u00a0years in New Zealand (NZ) and Ireland. Participants were to be randomised 2:1 to either HCQ (800\u00a0mg stat then 400\u00a0mg weekly) or no prophylaxis. The primary endpoint was time to Nucleic Acid Amplification Test-proven SARS-CoV-2 infection. Secondary outcome variables included mortality, hospitalisation, intensive care unit admissions and length of mechanical ventilation.<\/jats:p>\n                    <jats:p>The trial had no fixed sample size or duration of intervention. Bayesian adaptive analyses were planned to occur fortnightly, commencing with a weakly informative prior for the no prophylaxis group hazard rate and a moderately informative prior on the intervention log hazard ratio centred on \u2018no effect\u2019. Stopping for expected success would be executed if the intervention had a greater than 0.975 posterior probability of reducing the risk of SARS-CoV-2 infection by more than 10%. Final success would be declared if, after completion of 8\u00a0weeks of follow-up (reflecting the long half-life of HCQ), the prophylaxis had at least a 0.95 posterior probability of reducing the risk of SARS-CoV-2 infection by more than 10%. Futility would be declared if HCQ was shown to have less than a 0.10 posterior probability of reducing acquisition of SARS-CoV-2 infection by more than 20%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study did not begin recruitment due to the marked reduction in COVID-19 cases in NZ and concerns regarding the efficacy and risks of HCQ treatment in COVID-19. Nonetheless, the model presented can be easily adapted for other potential prophylactic agents and pathogens, and pre-established collaborative models like this should be shared and incorporated into future pandemic preparedness planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The decision not to proceed with the study was made before trial registration occurred.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06402-w","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T06:06:59Z","timestamp":1656310019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-0641","authenticated-orcid":false,"given":"Pepa","family":"Bruce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Ainscough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Hatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay R.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Brickell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cosgrave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Semprini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Morpeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"issue":"10223","key":"6402_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"key":"6402_CR2","unstructured":"World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. 2021. https:\/\/www.who.int. Accessed 25 Sep 2021."},{"key":"6402_CR3","unstructured":"World Health Organization (WHO). Coronavirus disease (COVID-19) Situation Report \u2013 162. 2020. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/20200630-covid-19-sitrep-162.pdf?sfvrsn=e00a5466_2. Accessed 25 Sep 2021."},{"issue":"6","key":"6402_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.006","volume":"80","author":"L Huang","year":"2020","unstructured":"Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16\u201323 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. J Infect. 2020;80(6):e1-13.","journal-title":"J Infect"},{"issue":"8","key":"6402_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782\u201393.","journal-title":"JAMA"},{"key":"6402_CR6","unstructured":"World Health Organisation (WHO)-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 25 Sep 2021."},{"key":"6402_CR7","unstructured":"Hancock F. Covid-19 in NZ Friday\u2019s numbers charted. Newsroom: COVID 19. 2020. https:\/\/www.newsroom.co.nz. Accessed 10 Jul 2020."},{"key":"6402_CR8","unstructured":"Government of Ireland. Statement from the National Public Health Emergency Team - Thursday 9 July. 2020. https:\/\/www.gov.ie\/en\/press-release\/8f1f2-statement-from-the-national-public-health-emergency-team-thursday-9-july. Accessed 10 Jul 2020."},{"issue":"5","key":"6402_CR9","doi-asserted-by":"publisher","first-page":"e209687","DOI":"10.1001\/jamanetworkopen.2020.9687","volume":"3","author":"VCC Cheng","year":"2020","unstructured":"Cheng VCC, Wong SC, Yuen KY. Estimating coronavirus disease 2019 infection risk in health care workers. JAMA Netw Open. 2020;3(5):e209687.","journal-title":"JAMA Netw Open"},{"key":"6402_CR10","unstructured":"Task force COVID-19 of the Department of Infectious Diseases and the IT Service Istituto Superiore di Sanit\u00e0. COVID-19 integrated surveillance data in Italy. Epicentro. https:\/\/www.epicentro.iss.it\/en\/coronavirus\/sars-cov-2-dashboard. Accessed 10 Jul 2020."},{"key":"6402_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/oemed-2020-106731","volume":"78","author":"M Mutambudzi","year":"2021","unstructured":"Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occup Environ Med. 2021;78:307\u201314.","journal-title":"Occup Environ Med"},{"issue":"1","key":"6402_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/occmed\/kqaa036","volume":"70","author":"D Koh","year":"2020","unstructured":"Koh D. Occupational risks for COVID-19 infection. Occup Med (Chic Ill). 2020;70(1):3\u20135.","journal-title":"Occup Med (Chic Ill)"},{"issue":"1","key":"6402_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/ajim.23199","volume":"64","author":"M Zhang","year":"2021","unstructured":"Zhang M. Estimation of differential occupational risk of COVID-19 by comparing risk factors with case data by occupational group. Am J Ind Med. 2021;64(1):39\u201347.","journal-title":"Am J Ind Med"},{"issue":"3","key":"6402_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.shaw.2020.06.001","volume":"11","author":"M Mhango","year":"2020","unstructured":"Mhango M, Dzobo M, Chitungo I, Dzinamarira T. COVID-19 risk factors among health workers: a rapid review. Saf Health Work. 2020;11(3):262\u20135.","journal-title":"Saf Health Work"},{"key":"6402_CR15","unstructured":"World Health Organization (WHO). COVID-19 Strategy Update. 2020. https:\/\/www.who.int\/publications\/m\/item\/covid-19-strategy-update. Accessed 25 Sep 2021."},{"key":"6402_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.","journal-title":"Virol J"},{"key":"6402_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1\u201310.","journal-title":"Cell"},{"key":"6402_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.","journal-title":"Cell Discov"},{"issue":"15","key":"6402_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732\u20139.","journal-title":"Clin Infect Dis"},{"key":"6402_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269\u201371.","journal-title":"Cell Res"},{"key":"6402_CR21","unstructured":"Medsafe. New Zealand Data Sheet Plaquenil - hydroxychloroquine sulfate. 2018. https:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/p\/Plaqueniltab.pdf. Accessed 10 Jul 2020."},{"key":"6402_CR22","unstructured":"MIMS New Zealand. . 2000. New Ethicals. 7th ed. Auckland. ADIS. Plaquenil. 1486-1488."},{"key":"6402_CR23","first-page":"CD013587","volume":"2","author":"B Singh","year":"2021","unstructured":"Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021;2:CD013587.","journal-title":"Cochrane Database Syst Rev"},{"key":"6402_CR24","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"6402_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrclinonc.2011.165","volume":"9","author":"DA Berry","year":"2012","unstructured":"Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012;9:199\u2013207.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"6402_CR26","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/jama.2012.4174","volume":"307","author":"WJ Meurer","year":"2012","unstructured":"Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? J Am Med Assoc. 2012;307(22):2377\u20138.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"6402_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/clpt.2009.68","volume":"86","author":"AD Barker","year":"2009","unstructured":"Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97\u2013100.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"6402_CR28","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.jclinepi.2013.02.015","volume":"66","author":"JT Connor","year":"2013","unstructured":"Connor JT, Elm JJ, Broglio KR. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013;66(8):S130\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"6402_CR29","first-page":"24","volume":"16","author":"D LeBlond","year":"2010","unstructured":"LeBlond D. FDA Bayesian statistics guidance for medical device clinical trials\u2014application to process validation. J Valid Technol. 2010;16(4):24\u201333.","journal-title":"J Valid Technol"},{"issue":"3","key":"6402_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515\u201326.","journal-title":"Biometrika"},{"issue":"1","key":"6402_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3325\/cmj.2019.60.50","volume":"60","author":"BK Hackenberger","year":"2019","unstructured":"Hackenberger BK. Bayes or not bayes, is this the question? Croat Med J. 2019;60(1):50\u20132.","journal-title":"Croat Med J"},{"key":"6402_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","volume":"383","author":"H Ikematsu","year":"2020","unstructured":"Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383:309\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"6402_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo YA. Baloxavir: first global approval. Drugs. 2018;78(6):693\u20137.","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1186\/s13063-022-06499-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06402-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T03:08:03Z","timestamp":1656990483000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06402-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6402"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06402-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-022-06499-z","URL":"https:\/\/doi.org\/10.1186\/s13063-022-06499-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was to be conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. Approval from the responsible local and\/or national human research ethics committee and competent authority for regulating clinical trials was to be obtained prior to the start of the study at each site; however, the decision to stop the study was made before such submissions could be made.Consent to participate was to be obtained from all participants prior to conducting any study related procedures. Participants were to receive no reimbursement for their time and participants were expected to incur no costs in attending study clinics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. For the survey data mentioned in the discussion, completion of the survey implied consent for the information provided to be used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}